$ADMA
ADMA BIOLOGICS, INC.

2022 Q1 Form 10-Q Financial Statement

#000114036122018668 Filed on May 11, 2022

View on sec.gov

Income Statement

Concept 2022 Q1 2021 Q1
Revenue $29.10M $16.05M
YoY Change 81.34% 57.34%
Cost Of Revenue $25.44M $17.77M
YoY Change 43.17% 5.59%
Gross Profit $3.662M -$1.722M
YoY Change -312.72% -74.03%
Gross Profit Margin 12.58% -10.73%
Selling, General & Admin $13.70M $10.03M
YoY Change 36.53% 19.03%
% of Gross Profit 374.1%
Research & Development $624.1K $987.6K
YoY Change -36.81% -35.39%
% of Gross Profit 17.04%
Depreciation & Amortization $1.400M $1.100M
YoY Change 27.27% 83.33%
% of Gross Profit 38.23%
Operating Expenses $18.48M $13.44M
YoY Change 37.45% -50.16%
Operating Profit -$14.82M -$15.16M
YoY Change -2.3% -9.57%
Interest Expense $3.389M $3.196M
YoY Change 6.05% 17.62%
% of Operating Profit
Other Income/Expense, Net -$10.19M -$3.216M
YoY Change 216.97% 29.9%
Pretax Income -$25.01M -$18.38M
YoY Change 36.06% -4.52%
Income Tax
% Of Pretax Income
Net Earnings -$25.01M -$18.38M
YoY Change 36.06% -4.5%
Net Earnings / Revenue -85.93% -114.53%
Basic Earnings Per Share -$0.13 -$0.16
Diluted Earnings Per Share -$0.13 -$0.16
COMMON SHARES
Basic Shares Outstanding 195.9M 115.7M
Diluted Shares Outstanding 195.9M 115.7M

Balance Sheet

Concept 2022 Q1 2021 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $69.50M $62.00M
YoY Change 12.1% -38.74%
Cash & Equivalents $69.50M $61.97M
Short-Term Investments
Other Short-Term Assets $5.519M $5.800M
YoY Change -4.84% 18.37%
Inventory $139.1M $94.15M
Prepaid Expenses
Receivables $25.63M $15.40M
Other Receivables $0.00 $0.00
Total Short-Term Assets $239.8M $177.3M
YoY Change 35.25% 7.13%
LONG-TERM ASSETS
Property, Plant & Equipment $53.22M $44.18M
YoY Change 20.47% 25.86%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $2.826M $2.200M
YoY Change 28.44% -37.14%
Total Long-Term Assets $68.23M $58.37M
YoY Change 16.9% 29.7%
TOTAL ASSETS
Total Short-Term Assets $239.8M $177.3M
Total Long-Term Assets $68.23M $58.37M
Total Assets $308.0M $235.7M
YoY Change 30.71% 11.96%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $14.12M $12.20M
YoY Change 15.7% 32.61%
Accrued Expenses $14.22M $8.100M
YoY Change 75.55% 76.09%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $31.57M $21.20M
YoY Change 48.9% 52.52%
LONG-TERM LIABILITIES
Long-Term Debt $138.4M $93.40M
YoY Change 48.2% -2.81%
Other Long-Term Liabilities $11.11M $41.97K
YoY Change 26374.11% -99.0%
Total Long-Term Liabilities $149.5M $41.97K
YoY Change 356227.68% -99.96%
TOTAL LIABILITIES
Total Short-Term Liabilities $31.57M $21.20M
Total Long-Term Liabilities $149.5M $41.97K
Total Liabilities $181.1M $123.2M
YoY Change 47.04% 7.85%
SHAREHOLDERS EQUITY
Retained Earnings -$358.8M
YoY Change
Common Stock $12.30K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $126.9M $112.5M
YoY Change
Total Liabilities & Shareholders Equity $308.0M $235.7M
YoY Change 30.71% 11.96%

Cashflow Statement

Concept 2022 Q1 2021 Q1
OPERATING ACTIVITIES
Net Income -$25.01M -$18.38M
YoY Change 36.06% -4.5%
Depreciation, Depletion And Amortization $1.400M $1.100M
YoY Change 27.27% 83.33%
Cash From Operating Activities -$26.01M -$33.23M
YoY Change -21.72% 34.82%
INVESTING ACTIVITIES
Capital Expenditures $2.842M $2.571M
YoY Change 10.54% 23.92%
Acquisitions
YoY Change
Other Investing Activities $0.00
YoY Change
Cash From Investing Activities -$2.842M -$2.571M
YoY Change 10.54% 24.04%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $41.91M
YoY Change 240.75%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 47.27M $41.84M
YoY Change 12.97% -58.65%
NET CHANGE
Cash From Operating Activities -26.01M -$33.23M
Cash From Investing Activities -2.842M -$2.571M
Cash From Financing Activities 47.27M $41.84M
Net Change In Cash 18.42M $6.045M
YoY Change 204.67% -91.88%
FREE CASH FLOW
Cash From Operating Activities -$26.01M -$33.23M
Capital Expenditures $2.842M $2.571M
Free Cash Flow -$28.86M -$35.80M
YoY Change -19.4% 33.97%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022Q1 dei Amendment Flag
AmendmentFlag
false
CY2022Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2022Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
CY2022Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2022Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001368514
CY2022Q1 adma Number Of Plasma Collection Facilities
NumberOfPlasmaCollectionFacilities
9
CY2022Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
29103093
CY2021Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
16048618
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
141172566
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
1641388
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
9569604
CY2022Q1 adma Vesting Of Restricted Stock Units Net Of Shares Withheld For Taxes And Retired Amount
VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAndRetiredAmount
-442636
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-25007857
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
126933065
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
88249426
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
781397
CY2021Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
41912515
CY2021Q1 adma Vesting Of Restricted Stock Units Net Of Shares Withheld For Taxes And Retired Amount
VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAndRetiredAmount
-59311
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-18379941
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
112504086
CY2021Q1 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2021Q1 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0
CY2022Q1 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0
CY2022Q1 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2022Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
200000
CY2021Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
200000
CY2022Q1 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
67900912
CY2021Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
64206927
CY2022Q1 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
14680432
CY2021Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
13271853
CY2022Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
53220480
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
50935074
CY2022Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1400000
CY2021Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1100000
CY2022Q1 adma Accrued Rebates Current
AccruedRebatesCurrent
6324746
CY2021Q4 adma Accrued Rebates Current
AccruedRebatesCurrent
5040200
CY2022Q1 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
2794447
CY2021Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
4739651
CY2022Q1 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
1565993
CY2021Q4 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
4066109
CY2022Q1 us-gaap Liability Premium Deficiency Testing On Long Duration Contract Amount
LiabilityPremiumDeficiencyTestingOnLongDurationContractAmount
674191
CY2021Q4 us-gaap Liability Premium Deficiency Testing On Long Duration Contract Amount
LiabilityPremiumDeficiencyTestingOnLongDurationContractAmount
1189970
CY2022Q1 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
2206409
CY2021Q4 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
1167072
CY2022Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
1260391
CY2022Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
1289679
CY2022Q1 us-gaap Lessee Operating Lease Liability Payments Due After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
5055880
CY2022Q1 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
13519101
CY2022Q1 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
5581019
CY2022Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
654003
CY2022Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
3088754
CY2021Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1011986
CY2022Q1 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
16654540
CY2021Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
17214988
CY2022Q1 adma Senior Notes Payable Before Debt Discount
SeniorNotesPayableBeforeDebtDiscount
151750000
CY2021Q4 adma Senior Notes Payable Before Debt Discount
SeniorNotesPayableBeforeDebtDiscount
100000000
CY2022Q1 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
13326948
CY2021Q4 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
5133761
CY2022Q1 us-gaap Senior Long Term Notes
SeniorLongTermNotes
138423052
CY2021Q4 us-gaap Senior Long Term Notes
SeniorLongTermNotes
94866239
CY2021Q4 us-gaap Preferred Stock Capital Shares Reserved For Future Issuance
PreferredStockCapitalSharesReservedForFutureIssuance
10000000
CY2022Q1 us-gaap Preferred Stock Capital Shares Reserved For Future Issuance
PreferredStockCapitalSharesReservedForFutureIssuance
10000000
CY2022Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2022Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
196347529
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
195813817
CY2022Q1 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
32811653
CY2022Q1 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
70840818
CY2022Q1 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
2.04
CY2021Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
2.82
CY2022Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
29103093
CY2021Q1 adma Cost Of Product Revenue Excluding Amortization Expense
CostOfProductRevenueExcludingAmortizationExpense
17770122
CY2021Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-15164249
CY2021Q1 adma Interest And Other Nonoperating Income Expense
InterestAndOtherNonoperatingIncomeExpense
-3215692
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-18379941
CY2021Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2571161
CY2021Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
1229628
CY2021Q1 us-gaap Assets
Assets
235667028
CY2022Q1 us-gaap Share Based Compensation
ShareBasedCompensation
1641388
CY2021Q1 us-gaap Share Based Compensation
ShareBasedCompensation
781397
CY2022Q1 adma Plasma Supply Agreement Term
PlasmaSupplyAgreementTerm
P10Y
CY2022Q1 adma Plasma Purchased
PlasmaPurchased
15500000
CY2022Q1 adma Percentage Of Inventory Purchases
PercentageOfInventoryPurchases
0.75
CY2021Q1 adma Plasma Purchased
PlasmaPurchased
12700000
CY2021Q1 adma Percentage Of Inventory Purchases
PercentageOfInventoryPurchases
0.72
CY2019Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2000000
CY2022Q1 adma Number Of Plasma Collection Facilities Under Development
NumberOfPlasmaCollectionFacilitiesUnderDevelopment
10
CY2022Q1 adma Number Of Fda Licensed Plasma Collection Facilities
NumberOfFDALicensedPlasmaCollectionFacilities
5
CY2022Q1 adma Cost Of Product Revenue Excluding Amortization Expense
CostOfProductRevenueExcludingAmortizationExpense
25441046
CY2022Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-14815066
CY2022Q1 adma Interest And Other Nonoperating Income Expense
InterestAndOtherNonoperatingIncomeExpense
-3522850
CY2022Q1 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-6669941
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-25007857
CY2022Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2842085
CY2022Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
1590217
CY2022Q1 us-gaap Assets
Assets
308032492
CY2021Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
16048618
CY2022Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
29103093
CY2021Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
16048618
CY2022Q1 adma Operating Lease Incremental Borrowing Rate Percent
OperatingLeaseIncrementalBorrowingRatePercent
0.13
CY2022Q1 us-gaap Operating Lease Expense
OperatingLeaseExpense
400000
CY2021Q1 us-gaap Operating Lease Expense
OperatingLeaseExpense
300000
CY2022Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
400000
CY2021Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
200000
CY2022Q1 adma Operating And Financing Lease Liability
OperatingAndFinancingLeaseLiability
7900000
CY2021Q4 adma Operating And Financing Lease Liability
OperatingAndFinancingLeaseLiability
8100000
CY2022Q1 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P8Y10M24D
CY2022Q1 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
1228526
CY2022Q1 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
1641603
CY2022Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
1517229
CY2022Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
1525793
CY2022Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
7284079
CY2022Q1 us-gaap Security Deposit
SecurityDeposit
44000
CY2022Q1 us-gaap Payments For Rent
PaymentsForRent
0
CY2022Q1 us-gaap Lessee Operating Lease Term Of Contract
LesseeOperatingLeaseTermOfContract
P126M
CY2022Q1 us-gaap Interest Paid Net
InterestPaidNet
2525987
CY2021Q1 us-gaap Interest Paid Net
InterestPaidNet
2751956
CY2022Q1 adma Equipment Acquired Reflected In Accounts Payable And Accrued Liabilities
EquipmentAcquiredReflectedInAccountsPayableAndAccruedLiabilities
1940425
CY2021Q1 adma Equipment Acquired Reflected In Accounts Payable And Accrued Liabilities
EquipmentAcquiredReflectedInAccountsPayableAndAccruedLiabilities
1797249
CY2022Q1 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
0
CY2021Q1 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
2073627
CY2022Q1 adma Warrants Issued In Connection With Notes Payable
WarrantsIssuedInConnectionWithNotesPayable
9569604
CY2021Q1 adma Warrants Issued In Connection With Notes Payable
WarrantsIssuedInConnectionWithNotesPayable
0

Files In Submission

Name View Source Status
0001140361-22-018668-index-headers.html Edgar Link pending
0001140361-22-018668-index.html Edgar Link pending
0001140361-22-018668.txt Edgar Link pending
0001140361-22-018668-xbrl.zip Edgar Link pending
adma-20220331.xsd Edgar Link pending
adma-20220331_cal.xml Edgar Link unprocessable
adma-20220331_def.xml Edgar Link unprocessable
adma-20220331_lab.xml Edgar Link unprocessable
adma-20220331_pre.xml Edgar Link unprocessable
brhc10037445_10q.htm Edgar Link pending
brhc10037445_10q_htm.xml Edgar Link completed
brhc10037445_ex31-1.htm Edgar Link pending
brhc10037445_ex31-2.htm Edgar Link pending
brhc10037445_ex32-1.htm Edgar Link pending
brhc10037445_ex32-2.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending